Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 13, 2016 8:00 PM ET


Company Overview of Galera Therapeutics, Inc.

Company Overview

Galera Therapeutics, Inc., a clinical-stage biotechnology company, develops drugs targeting oxygen metabolic pathways. The company primarily focuses on the prevention of radiation-induced toxicity, including mucositis, and the treatment of cancer. Its small molecule dismutase mimetics mimics the activity of the human superoxide dismutase enzymes. The company was founded in 2009 and is based in Malvern, Pennsylvania.

2 West Liberty Boulevard

Suite 110

Malvern, PA 19355

United States

Founded in 2009



Key Executives for Galera Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 58
Founder, Chief Operating Officer and Director
Chief Financial Officer
Age: 66
Chief Medical Officer
Director of Business Development
Compensation as of Fiscal Year 2015.

Galera Therapeutics, Inc. Key Developments

Galera Therapeutics Announces Fast Track Designation of GC4419 for Prevention of Oral Mucositis

Galera Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for GC4419, an investigational drug candidate, for the reduction of severity and incidence of radiation and chemotherapy induced oral mucositis (OM). Galera also announced that it has begun enrolling patients in a Phase 2b study of GC4419 for the reduction of OM in head and neck cancer (HNC) patients. The FDA Fast Track process is designed to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. This designation provides for more frequent consultation between the FDA and the sponsor, as well as the potential "rolling review" of completed sections of the New Drug Application (NDA), and potential eligibility for accelerated approval and priority review. Based on Phase 1b/2a trial results of GC4419 in HNC patients receiving chemoradiation therapy, Galera has begun enrolling patients in a double-blind, randomized Phase 2b clinical trial to prevent OM in this setting.

Galera Therapeutics Appoints Thomas Dyrberg to the Board of Directors

Galera Therapeutics, Inc. announced it has completed a $37 million Series B financing. The Series B financing was led by Novo Ventures, with participation from existing investors New Enterprise Associates, Novartis Venture Fund (NVF), Correlation Ventures and Galera Angels. Dr. Thomas Dyrberg, Managing Partner of Novo Ventures, will join the Galera Board of Directors.

Galera Therapeutics, Inc. Presents at Boston CEO Conference, May-27-2015 01:00 PM

Galera Therapeutics, Inc. Presents at Boston CEO Conference, May-27-2015 01:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, United States. Speakers: Robert A. Beardsley, Executive Chair of the Board of Directors.

Similar Private Companies By Industry

Company Name Region
X-Chem, Inc. United States
Alacritas Biopharma, Inc. United States
Metabiota, Inc. United States
BASF Plant Science L.P. United States
Ganeden, Inc. United States

Recent Private Companies Transactions

Private Placement
October 1, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Galera Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at